Ignite Creation Date:
2024-05-06 @ 6:53 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05813600
Status:
COMPLETED
Last Update Posted:
2023-04-14
First Post:
2023-04-07
Brief Title:
Efficacy and Safety of NirmatrelvirRitonavir for Treating Omicron Variant of COVID-19
Sponsor:
Xiangao Jiang
Organization:
Wenzhou Central Hospital
Study Overview
Official Title:
To Evaluate the Efficacy and Safety of NirmatrelvirRitonavir in the Treatment of the Omicron Variant of COVID-19
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to evaluate the efficacy and safety of NirmatrelvirRitonavir in the treatment of the Omicron variant of COVID-19 The main question it aims to answer is Whether the use of the drug can help patients recover from COVID-19
Patients in both groups were given Lianhua Qingwen Capsule orally 3 timesday 6 gtime oral antipyretic ibuprofen suspension 10ml and symptomatic supportive treatment for body temperature 385 The study group was given Nirmatrelvir 300mgRitonavir 100mg orally q12h for 5 days and the control group not given any antiviral drugs
Patients in both groups were given Lianhua Qingwen Capsule orally 3 timesday 6 gtime oral antipyretic ibuprofen suspension 10ml and symptomatic supportive treatment for body temperature 385 The study group was given Nirmatrelvir 300mgRitonavir 100mg orally q12h for 5 days and the control group not given any antiviral drugs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None